Results 71 to 80 of about 152,178 (350)

Efficient Preparation of Homogenous Antibody Conjugates via Glycosite‐Specific Transglycosylation Enabled by Readily Available Glycosyl Donors

open access: yesAngewandte Chemie, EarlyView.
A streamlined platform for glycosite‐specific antibody conjugation is enabled by LacNAc‐derived cyclic acetal donors, which can be prepared in only two steps and used directly in single‐enzyme Endo S2‐mediated transglycosylation. The platform supports the broad construction of homogeneous gsADCs and gsDACs, with donor 7 producing glycoengineered ...
Deqin Cai   +13 more
wiley   +2 more sources

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

open access: yesBiomedicines, 2022
Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment.
Dmitrii Kamashev   +7 more
doaj   +1 more source

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2021
Significance This study demonstrates the efficacy of combining macrophage-checkpoint inhibition with tumor-specific antibodies for cancer immunotherapy.
Rosalynd Upton   +13 more
semanticscholar   +1 more source

Resistance to Trastuzumab

open access: yesCancers, 2022
Simple Summary Trastuzumab is a humanized antibody that has significantly improved the management and treatment outcomes of patients with cancers that overexpress HER2.
S. Vivekanandhan, K. Knutson
semanticscholar   +1 more source

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

open access: yesPharmaceuticals, 2021
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
Steven Simoens   +2 more
doaj   +1 more source

Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. [PDF]

open access: yes, 2016
Patient-derived xenograft (PDX) mouse models of cancer are emerging as an important component of personalized precision cancer therapy. However, most models currently offered to patients have their tumors subcutaneously-transplanted in immunodeficient ...
Bouvet, Michael   +10 more
core   +2 more sources

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

open access: yesFEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu   +5 more
wiley   +1 more source

Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab [PDF]

open access: yes, 2012
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition
A. c. Wolff   +12 more
core   +1 more source

EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer

open access: yesAdvanced Science, EarlyView.
This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv   +8 more
wiley   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

open access: yes, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L.   +4 more
core   +5 more sources

Home - About - Disclaimer - Privacy